Drug Trial Radar · NCT04620148
TAK-242 in Patients With Acute Alcoholic Hepatitis
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
4
Actual
Start
Nov 12, 2020
Primary completion
Mar 31, 2022
Study completion Mar 31, 2022
Sponsor
- Lead sponsor
- Akaza Bioscience LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of alcohol-related cirrhosis due to alcoholic hepatitis resulting in acute-on-chronic liver failure.
Conditions
- Acute-On-Chronic Liver Failure
Interventions
TAK-242Drug
TAK-242 concentrate solution 80 mg/mL for dilution and infusion
PlaceboDrug
Matching placebo concentrate solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in CLIF-C Acute-on-chronic Liver Failure (CLIF-C ACLF) Score From Baseline to Day 8Time frame: Baseline to Day 8
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Kings College Hospital
London, United Kingdom
Nottingham University Hospital Queen's Medical Centre
Nottingham, United Kingdom
Derriford Hospital
Plymouth, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.